---
title: "Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295408255.md"
description: "Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX) with a $115 price target. This follows a Buy from Canaccord Genuity, while J.P. Morgan held a Hold rating. The report highlights Flynn's strong track record in the healthcare sector."
datetime: "2026-08-10T12:26:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295408255.md)
  - [en](https://longbridge.com/en/news/295408255.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295408255.md)
generator: "portal-rs"
---

# Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE, with a price target of $115.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Flynn covers the Healthcare sector, focusing on stocks such as Biogen, Gilead Sciences, and Johnson & Johnson. According to TipRanks, Flynn has an average return of 10.8% and a 59.64% success rate on recommended stocks. 

In addition to Morgan Stanley, BioNTech SE also received a Buy from Canaccord Genuity’s John Newman in a report issued on August 5. However, on August 6, J.P. Morgan maintained a Hold rating on BioNTech SE (NASDAQ: BNTX).

### Related Stocks

- [BNTX.US](https://longbridge.com/en/quote/BNTX.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [BioNTech (BNTX) Halts Cancer Trial, Is The 15% Undervaluation Still Credible?](https://longbridge.com/en/news/297786944.md)
- [BioNTech Kills a Cancer Trial Roche Helped Build](https://longbridge.com/en/news/297359309.md)
- [BioNTech to terminate mid-stage trial of mRNA cancer vaccine](https://longbridge.com/en/news/297334714.md)
- [Jefferies Sticks to Their Buy Rating for BioNTech SE (BNTX)](https://longbridge.com/en/news/294871383.md)
- [Bernstein Sticks to Their Hold Rating for BioNTech SE (BNTX)](https://longbridge.com/en/news/294859038.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**